Analyses / Public Summary / 119 · S 3944 Public Summary

119-S-3944 Journalist Public Summary

119 · S 3944 Women’s Heart Health Expansion Act of 2026

Reauthorizes and expands a CDC program to prevent heart disease in women by funding screenings, education, and follow‑up care, with $250 million authorized for FY2027–2031; requires a GAO study; last action was a Senate HELP Committee hearing on March 19, 2026.

Published
20 Mar 2026
Updated
20 Mar 2026
Tags
Public Summary · U.S. Senate · Health Policy
Unvetted
01 · Section

Headline Summary

A bipartisan bill to renew and expand a CDC program that screens women for heart‑disease risks, funds education and follow‑up care, and authorizes $250 million for 2027–2031.

02 · Section

What It Does

S. 3944, the “Women’s Heart Health Expansion Act of 2026,” would reauthorize the WISEWOMAN program (Well‑Integrated Screening and Evaluation for Women Across the Nation) under the Public Health Service Act. It lets the CDC award supplemental grants so clinics can add cardiovascular risk screenings (like blood pressure, cholesterol, and obesity), provide evidence‑based health education to improve outcomes (e.g., blood pressure, cholesterol, diabetes, obesity), make referrals with follow‑up, and evaluate/report results. It authorizes $250,000,000 for fiscal years 2027–2031 and directs the Government Accountability Office to report by September 30, 2027 on who’s eligible, participation trends, barriers to screening, and cost‑effectiveness.

  • Authorizes CDC supplemental grants to expand preventive services for women.
  • Covers screenings, health education, referrals, and program evaluation/reporting.
  • Targets women already eligible under existing programs and other high‑risk women defined by the Secretary of HHS.
  • Authorizes $250 million over FY2027–FY2031.
  • Requires a GAO study by September 30, 2027 on reach, barriers, trends, and cost‑effectiveness.
03 · Section

Who’s For It

  • Lead sponsors: Sen. Angela Alsobrooks (D‑MD) and Sen. Katie Britt (R‑AL), signaling bipartisan interest in women’s cardiovascular health.
  • Supporters’ rationale (as reflected in the bill’s design): expanding access to preventive screenings and education, improving measurable outcomes, and ensuring referrals and follow‑up for high‑risk women.
04 · Section

Who’s Against It

  • No formal opposition noted in the provided record to date.
  • Potential concerns often raised with similar bills: overall cost ($250 million authorization), overlap with existing programs, how “high‑risk” eligibility is defined by HHS, and whether federal grants duplicate services better handled in primary care.
05 · Section

What’s Next

Status: Introduced in the Senate on February 26, 2026; read twice and referred to the Health, Education, Labor, and Pensions (HELP) Committee; committee hearings were held on March 19, 2026. Next steps typically include a committee markup and vote; if approved, the bill would move to the full Senate, then to the House, and finally to the President.

Discussion